Armistice Capital’s IO Biotech IOBT Stock Holding History

Armistice Capital’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,545,000	Closed	-$1.81M	–	295
2024 Q2	$1.81M	Sell	1,545,000 -179,000	-10%	-$250K	0.02%	148
2024 Q1	$2.98M	Sell	1,724,000 -200,000	-10%	-$347K	0.04%	135
2023 Q4	$3.62M	Sell	1,924,000 -224,000	-10%	-$267K	0.05%	135
2023 Q3	$3.03M	Buy	+2,148,000	New	+$3.78M	0.05%	123

Other funds holding IOBT

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Armistice Capital's IOBT Position: Q3 2024 in Review

Armistice Capital sold out of IO Biotech (IOBT) in Q3 2024, closing a stake of 1,545,000 shares — an estimated $1.81M sold.

Armistice Capital first reported a position in IOBT in Q3 2023 and held it in 4 quarters. The position peaked at $3.62M in Q4 2023. 20 funds tracked by Wall St. Rank hold IOBT as of Q3 2024.

Armistice Capital reported no remaining IO Biotech position as of Q3 2024 after selling out during the quarter.
Armistice Capital sold 1,545,000 IO Biotech shares in Q3 2024, an estimated $1.81M.
Armistice Capital first reported a position in IO Biotech in Q3 2023 and held it in 4 quarters.
Armistice Capital's IO Biotech position peaked at $3.62M in Q4 2023.
20 funds tracked by Wall St. Rank held IO Biotech as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.